No, no, no, Tharos, you are missing the point. As I have stated previously, I believe BPI does show promise in combating this malady. Ignoring potential pitfalls, however, that may arise in the utilization of rBPI21 as a therapeutic treatment, will not make them disappear. Endotoxins may be only part of the picture as the excerpt below
(Natanson, et al.) from my previous post illustrates:
Targeting a single microbial toxin such as endotoxin may not represent a viable strategy for treating a complex inflammatory response to diverse gram-negative bacteria. Similarly, the strategy
of inhibiting the host inflammatory response may not be beneficial
because immune cells and cytokines play both pathogenic and protective roles. Finally, our scientific knowledge of the complex timing of mediator release and balance during sepsis may be insufficient to develop successful therapeutic interventions for this syndrome. |
